- At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) provided an overview of Ligand’s corporate structure and business following the successful spin-off of its OmniAb antibody discovery business.
- Management also introduced 2023 financial guidance.
- Related: Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger.
- The management reviewed Ligand’s role in manufacturing Veklury (remdesivir) to treat COVID-19 and highlighted that cumulative sale of Captisol related to COVID between 2020 and 2022 are expected to exceed $300 million, providing Ligand with significant non-dilutive capital.
- The company forecasts FY23 core revenue of $118-$122 million, including $72-$76 million from royalties, $21 million from sales of Captisol (excluding COVID-related sales) and $25 million from contract revenue.
- It forecasts adjusted diluted EPS of $3.10-$3.30 versus the consensus of $2.99.
- Excluding COVID-related Captisol sales, the company’s FY22 outlook was for revenue of $99 million – $104 million and adjusted EPS of $2.05 to $2.20, as per the company’s Q3 report.
- Ligand estimates that at the end of 2022, it will have $150 million of cash and investments to fund its M&A initiatives.
- Price Action: LGND shares are down 1.44% at $63.87 on the last check Tuesday.
Ligand Pharma Issues Mixed Guidance For FY23
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its OmniAb antibody discovery business.
Related Posts
Hempacco Receives Notification Of Deficiency From Nasdaq
Hempacco Co, Inc. (NASDAQ:HPCO) ("Hempacco" or the "Company"), a vertically integrated hemp manufacturing company, announced today that on April 20, 2023, it received a written notice (the
$1M Bet On Glatfelter? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by over 70 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Walgreens Q4 Profit, Annual Outlook Falls Short Of Expectations On Lower Demand For Covid Vaccines, Tests
Walgreens Boots Alliance Inc's (NASDAQ: WBA) Q4 FY23 sales increased 9.2% Y/Y to $35.4 billion, up 8.3% on a constant currency basis, beating the consensus of $34.82 bill